FSHR and ovarian cancer: Alfredo, et al. were able to generate a robust CD4+ and CD8+ cellular immune response against ovarian cancer in murine models with a DNA vaccine targeting follicle-stimulating hormone receptor (FSHR) in an pVAX1 expression vector with three doses administered 2 weeks apart using electroporation.